Healthcare [ 10/13 ] | Biotechnology [ 67/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0 Increased by +100% | -0.02 Increased by +100% |
| Nov 3, 23 | -0 Increased by +99.53% | -0.1 Increased by +97.8% |
| Sep 14, 23 | -0.6 Decreased by -33.33% | -0.41 Decreased by -46.34% |
| May 22, 23 | -0.6 Increased by +34.78% | -0.41 Decreased by -46.34% |
| Mar 31, 23 | -0.4 Increased by +56.52% | -0.41 Increased by +2.44% |
| Nov 21, 22 | -0.47 Increased by +75.77% | -0.17 Decreased by -176.47% |
| Aug 16, 22 | -0.45 Increased by +18.18% | -0.06 Decreased by -650% |
| Apr 1, 22 | -0.92 Decreased by -19.48% | -0.41 Decreased by -124.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 417 K Increased by +N/A% | -83 K Increased by +99.08% | Decreased by -19.9% Decreased by N/A% |
| Jun 30, 23 | 19.65 M Increased by +6.63 K% | 12.14 M Increased by +247.72% | Increased by +61.81% Increased by +102.2% |
| Mar 31, 23 | 0 Decreased by -100% | -5.35 M Increased by +47.65% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by -100% | -6.39 M Increased by +37.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by -100% | -9.07 M Increased by +56.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 292 K Increased by +784.85% | -8.22 M Decreased by -49.74% | Decreased by -2.82 K% Increased by +83.08% |
| Mar 31, 22 | 570 K Increased by +8.04 K% | -10.23 M Decreased by -48.41% | Decreased by -1.79 K% Increased by +98.18% |
| Dec 31, 21 | 570 K Increased by +N/A% | -10.23 M Decreased by -75.63% | Decreased by -1.79 K% Decreased by N/A% |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.